Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    Acetohexamide

    go.drugbank.com/drugs/DB00414
    ApprovedWithdrawn

    A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.

    Categories: Drugs Used in Diabetes, combinations of sulfonamidesSynonyms: N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea, 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
  2. Drug

    Streptococcus pneumoniae type 19a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10337
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 19a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19a of *Streptococcus pneumoniae

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  3. Drug

    Fosgemcitabine palabenamide

    go.drugbank.com/drugs/DB15057
    Investigational

    NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).

    Categories: Heterocyclic Compounds, 1-RingSynonyms: L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester
  4. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. … It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

    Categories: GI Motility Alteration, Digestive/GI System Activity AlterationSynonyms: N-methyl quinuclidinyl benzilate, Bromuro de clidinio
  5. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

    Synonyms: DP-VPA
  6. Pathway

    Mycophenolic Acid Action Pathway

    smpdb.ca/view/SMP0122722
    Drug action

    Mycophenolic acid is administered orally in the form of a delayed release tablet. … This step in the purine de novo pathway is the first commited step towards guanosine/guanine synthesis and it's inhibition blocks all route to produce the nucleotide.

    Drugs: Tetrahydrofolic acid · Aspartic acid · L-Glutamine · Adenosine phosphate · Glutamic acid · Glycine +14 more
  7. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. … FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 Inducers
  8. Drug

    Soy isoflavones

    go.drugbank.com/drugs/DB14101
    Approved

    Mixtures: D-Cal SoyCal, CALCIBON D SOYA FORTE TABLETASProducts: FITOFLAVONA® 35 MG, APROLAC® 80 MGTABLETAS
  9. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242417] Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

    Categories: Mammalian target of rapamycin (mTOR) kinase inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: LIKMUN-E, P-HYSPLAN
  10. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.

    Categories: Sensitizers Used in Photodynamic/radiation Therapy, Heterocyclic Compounds with 4 or More Rings